| Drug Name |
Alemtuzumab |
| Drug ID |
BADD_D00064 |
| Description |
Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. |
| Indications and Usage |
Alemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia. |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AA34 |
| DrugBank ID |
DB00087
|
| KEGG ID |
D02802
|
| MeSH ID |
D000074323
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D01ZYG
|
| NDC Product Code |
58468-0200; 58468-0357 |
| UNII |
3A189DH42V
|
| Synonyms |
Alemtuzumab | Campath 1H | Monoclonal Antibody Campath-1H | Antibody Campath-1H, Monoclonal | Campath-1H, Monoclonal Antibody | Monoclonal Antibody Campath 1H | Campath-1H | Campath1H | Campath 1M | Campath-1M | MabCambath | Lemtrada | Campath 1G | Campath-1-G | Campath 1 G | Campath1G | Campath-1G | Campath |
